Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice

CompletedOBSERVATIONAL
Enrollment

3,520

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

November 8, 2023

Study Completion Date

November 8, 2023

Conditions
Chronic Obstructive Pulmonary Disease
Trial Locations (40)

100070

Research Site, Beijing

200433

Research Site, Shanghai

211100

Research Site, Nanjing

214002

Research Site, Wuxi

223800

Research Site, Nanjing

250012

Research Site, Jinan

261041

Research Site, Weifang

310005

Research Site, Hangzhou

317000

Research Site, Taizhou

318000

Research Site, Taizhou

321000

Research Site, Jinhua

451100

Research Site, Xinzheng

510120

Research Site, Guangzhou

510150

Research Site, Guangzhou

510620

Research Site, Guangzhou

518039

Research Site, Shenzhen

518055

Research Site, Shenzhen

518100

Research Site, Shenzhen

570311

Research Site, Haikou

610016

Research Site, Chengdu

621000

Research Site, Mianyang

710000

Research Site, Xi'an

710100

Research Site, Xi'an

Unknown

Research Site, Beijing

Research Site, Chengdu

Research Site, Chifeng

Research Site, Chongqing

Research Site, Guangyuan

Research Site, Haikou

Research Site, Haining

Research Site, Hangzhou

Research Site, Huizhou

Research Site, Jiaxing

Research Site, Xinxiang

Research Site, Yinchuan

Research Site, Zhengzhou

Research Site, Zibo

046000

Research Site, Changzhi

030600

Research Site, Jinzhong

045000

Research Site, Yangquan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY